Phase 3 a long-term administration study of NTa53

Phase 3 a long-term administration study of NTa53 in Patients with Allergic Conjunctivitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031240352

Enrollment

120

Registered

2024-09-26

Start date

2024-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Interventions

56-day Administration of NTa53

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Provided signed, written informed consent. -Has a positive result from a Type I allergy test.

Exclusion criteria

Exclusion criteria: -Eye disease other than allergic conjunctivitis is present and requires treatment. -Other protocol-specified exclusion criteria may apply.

Design outcomes

Primary

Measure	Time frame
Safety (Adverse Events, Ophthalmologic Examination and Clinical Examination) Efficacy (Subjective Ocular Symptom Score, Objective Ocular Findings Score, Quality Of Life Survey)	—

Contacts

Public ContactTakeshi Yonemichi

Nitto Medic Co., Ltd.

clinical@nittomedic.co.jp+81-76-455-3541

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026